About the Company
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AKTX News
Akari Therapeutics enters merger deal with Peak Bio
Akari Therapeutics has signed an agreement with Peak Bio to merge in an all-stock transaction, creating a diversified ...
Akari Therapeutics, Peak Bio Announces Agreement To Merge As Equals - Quick Facts
Akari Therapeutics, Plc (AKTX) and Peak Bio Inc. announced a definitive agreement to merge as equals in an all-stock deal. The ...
Akari Therapeutics Plc Sponsored ADR
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases.
Akari Therapeutics PLC (AKTX)
Akari Therapeutics, Plc (NASDAQ:AKTX) announced that the FDA has granted an orphan drug designation to its lead pipeline candidate nomacopan for the treatment of bullous ...
AKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Akari Therapeutics, Plc (NASDAQ: AKTX) and Peak Bio Inc. is fair to Akari shareholders. The investigation concerns ...
Akari Therapeutics PLC (CLA.BE)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Akari Therapeutics PLC ADR
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Akari Therapeutics, Plc (AKTX)
For example, although Amazon.com... Simply Wall St. Insiders rewarded with a US$607k addition on top of their US$1.3m purchase as Akari Therapeutics, Plc (NASDAQ:AKTX) hits US$22m Last week, Akari ...
Akari Therapeutics, Plc (AKTX)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...